6.1.1 Recombinant human insulin was the first therapeutic produced with recombinant DNA technology and was the first such product that was expressed in E. coli. Today the sheer volumes of insulin production dominate the microbial biologics market.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
6.2.1 More recently, a new class of drugs has come to share a dominant position in the microbial biologics market with insulin: glucagon-like peptide-1 (GLP-1) agonists. These drugs generally consist of a peptide backbone that is about 37 amino acids long with a large fatty acid moiety covalently bound to the peptide.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
6.3.1 To approximate the landscape of insulin and novel GLP-1 drugs in clinical trials, we analyzed the clinical trials that are described as an “insulin” but removed the data from trials that are only measuring insulin levels. We also included drugs that were identified as GLP-1, semaglutide, glucagon, or any of the named GLP-1 agonists. We identified a total of 3,695 interventional trials that were initiated between January 1, 1982, and July 15, 2024, with our search.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.